| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥13471.2B | ¥13914.8B | -3.2% |
| Operating Income | ¥466.8B | ¥890.4B | -47.6% |
| Profit Before Tax | ¥450.4B | ¥846.5B | -46.8% |
| Net Income | ¥310.5B | ¥747.7B | -58.5% |
| ROE | 4.3% | 10.8% | - |
FY2025 consolidated results: Revenue 1,347.1B yen (YoY -3.2%), Operating Income 46.7B yen (YoY -47.6%), Ordinary Income 33.6B yen (YoY -58.0%), Net Income attributable to parent 29.0B yen (YoY -60.5%). Revenue remained relatively stable with minimal decline, but profitability deteriorated significantly across all profit levels. Operating margin contracted to 3.5% from 6.4% YoY, driven primarily by impairment losses of 51.0B yen (increased from 23.9B yen prior year) and elevated other expenses of 29.0B yen. The sharp margin compression represents a clear inflection point, reversing the prior period's profitability trend. ROE declined to 4.3% from 12.0% YoY, falling to approximately one-third of the prior year level. Despite weak reported earnings, operating cash flow remained robust at 130.3B yen, generating positive free cash flow of 43.2B yen after substantial capital expenditures of 106.7B yen.
Revenue declined 3.2% YoY to 1,347.1B yen, with mixed performance across segments following organizational restructuring. Semiconductor and Electronic Materials segment grew revenue 13.7% YoY to 506.3B yen, driven by strong demand for high-purity gases and CMP slurries in the semiconductor front-end materials subsegment. This growth was offset by declines in other segments: Mobility decreased 10.9% to 178.4B yen due to automotive market headwinds, Innovation Enabling Materials fell 4.9% to 92.2B yen, Chemicals contracted 14.0% to 174.4B yen, and Crassus Chemical (newly separated petrochemical business) declined 8.9% to 300.3B yen. The January 2025 organizational restructuring created the new Crassus Chemical segment through an absorption-type split of the petrochemical business from Resonac and the parent company, while also transferring the carbon anode materials business from Mobility to Chemicals. These structural changes complicate direct YoY comparisons but reflect strategic portfolio rationalization.
Operating income plummeted 47.6% YoY to 46.7B yen, with operating margin compressing 2.9 percentage points to 3.5%. Core operating profit (excluding non-recurring items) was 109.1B yen, but this was heavily impacted by impairment losses of 51.0B yen (more than double the 23.9B yen prior year), other expenses of 29.0B yen (up from 17.8B yen), and reduced other income of 17.6B yen (down from 38.7B yen). Segment-level core operating profitability varied dramatically: Semiconductor and Electronic Materials delivered 108.4B yen core operating profit with 21.2% margin (up from 16.4% prior year), while Chemicals posted a loss of 5.5B yen (margin -3.1%) and Mobility profit fell 31.0% to 4.4B yen. The substantial impairment charges were concentrated in Mobility (24.9B yen) and Chemicals (3.4B yen) segments, indicating asset write-downs related to automotive and basic chemicals businesses. Other expenses increased 62.6%, likely reflecting restructuring costs associated with the organizational reorganization. Corporate unallocated costs expanded significantly to 17.7B yen from 10.0B yen, reflecting elevated group-level R&D and administrative expenses.
The gap between operating income (46.7B yen) and net income (29.0B yen) widened significantly. Financial expenses net of income resulted in a 10.9B yen burden (interest expense 13.5B yen partially offset by interest and dividend income 3.7B yen), while equity method investment gains contributed 9.3B yen. Income tax expense was 14.0B yen, representing an effective tax rate of 31.1% on pretax income of 45.0B yen. The modest equity method gains and elevated net financial costs (due to substantial debt of 946.6B yen in bonds and borrowings) compressed post-operating profitability. Non-controlling interests were minor at 2.0B yen. This represents a revenue down/profit down pattern, with the profit decline far exceeding the revenue contraction due to non-recurring impairment charges, restructuring costs, and operational deleveraging in lower-margin segments.
Semiconductor and Electronic Materials is the core business, contributing 37.6% of total revenue and generating 108.4B yen in core operating profit with an industry-leading 21.2% core operating margin. This segment showed strong momentum with revenue growing 13.7% YoY and core operating profit increasing 47.0% YoY, driven by robust demand for semiconductor materials including high-purity gases, CMP slurries, epoxy encapsulants, and SiC epitaxial wafers. Mobility generated 178.4B yen revenue (13.2% of total) with 4.4B yen core operating profit and 2.5% margin, representing significant deterioration from 6.3B yen profit and 3.2% margin prior year due to automotive market weakness and a major 24.9B yen impairment charge. Innovation Enabling Materials produced 92.2B yen revenue (6.8% of total) with 10.4B yen core operating profit and 11.2% margin, maintaining relatively stable profitability. Chemicals reported 174.4B yen revenue (12.9% of total) but posted a 5.5B yen core operating loss (margin -3.1%), deteriorating from 1.8B yen profit prior year, impacted by weak demand for basic chemicals and industrial gases plus 3.4B yen in impairment charges. Crassus Chemical, the newly separated petrochemical business, contributed 300.3B yen revenue (22.3% of total) with 4.7B yen core operating profit and 1.6% margin, down from 8.6B yen profit prior year due to unfavorable petrochemical spreads. The substantial margin disparity between Semiconductor and Electronic Materials (21.2%) and other segments (averaging 1-3%) highlights concentration of profitability in high-value specialty materials versus commoditized chemicals and automotive components.
[Profitability] ROE declined sharply to 4.3% from 12.0% YoY, significantly underperforming both the company's historical average and falling to roughly one-third of prior year levels. Operating margin compressed 2.9 percentage points to 3.5% from 6.4% YoY, driven by impairment charges and elevated SG&A expenses. Gross profit margin improved slightly to 24.0% from 22.4%, but this was entirely offset by increased SG&A ratio of 19.7% (up 2.2 percentage points) reflecting higher corporate costs and restructuring expenses. Net profit margin collapsed to 2.2% from 5.4% YoY. The DuPont analysis reveals ROE deterioration stemmed primarily from margin compression (net profit margin 2.2%) rather than asset efficiency (total asset turnover 0.64x, relatively stable) or leverage changes (financial leverage 2.9x, slightly reduced from deleveraging). [Efficiency] Total asset turnover was 0.64x. Inventory turnover was calculated at 73 days (using COGS/inventory), indicating slower inventory velocity compared to typical chemical industry benchmarks of 50-60 days and signaling potential inventory obsolescence or demand weakness. [Cash Quality] Cash and cash equivalents stood at 261.9B yen, providing 1.55x coverage of current bonds and borrowings of 169.6B yen, indicating adequate short-term liquidity. Operating cash flow of 130.3B yen represented a strong 4.20x coverage of net income, confirming high earnings quality despite weak reported profitability. The operating CF to net income ratio exceeding 4.0x reflects substantial add-backs for non-cash impairment charges and depreciation. [Financial Health] Equity ratio improved to 34.5% from 31.9% YoY, driven by debt reduction despite weak earnings. Total debt (bonds and borrowings) decreased to 946.6B yen from 996.3B yen, with long-term debt declining 9.5% to 777.0B yen reflecting active deleveraging through 165.2B yen in long-term debt repayments and 60.0B yen in bond redemptions. Debt-to-equity ratio improved to 1.30x from 1.44x YoY. The pension surplus (retirement benefit assets) expanded to 49.4B yen from 38.5B yen, providing additional balance sheet strength.
Operating cash flow of 130.3B yen represents 4.20x coverage of net income of 31.0B yen, confirming strong cash-backed earnings quality despite significant non-cash impairment charges. Cash flow from operations before working capital changes was 148.8B yen, with working capital providing a modest 3.6B yen headwind primarily from increased receivables of 19.1B yen, partially offset by favorable inventory reduction of 1.8B yen and increased payables of 5.9B yen. Income taxes paid of 16.8B yen and interest paid of 12.9B yen represented manageable cash outflows. Investing cash flow was negative 87.1B yen, dominated by capital expenditures of 106.7B yen for semiconductor materials capacity expansion and maintenance investments, partially offset by 20.6B yen in subsidiary disposal proceeds and 4.7B yen from property sales. Free cash flow generation of 43.2B yen (operating CF 130.3B yen minus investing CF 87.1B yen) covered dividend payments of 11.8B yen by 3.66x, indicating strong dividend sustainability. Financing cash flow was negative 69.9B yen, reflecting strategic deleveraging with long-term debt repayments of 165.2B yen and bond redemptions of 60.0B yen, partially offset by new long-term borrowings of 144.7B yen and short-term debt increases of 18.5B yen. The net debt reduction of approximately 50B yen improved financial flexibility. Cash and equivalents decreased 32.7B yen to 261.9B yen, with 15.7B yen transferred to assets held for sale and a positive 9.8B yen foreign exchange translation effect. The company maintains adequate liquidity with cash covering 1.55x of short-term debt and strong operating cash generation supporting continued capital investment and shareholder returns despite near-term profitability headwinds.
Operating income of 46.7B yen versus ordinary income (pretax income) of 45.0B yen indicates a modest 1.7B yen net burden from non-operating items. This comprises net financial costs of 10.9B yen (financial expenses 17.0B yen including 13.5B yen interest expense minus financial income 6.1B yen including 2.8B yen interest and dividend income) offset by equity method investment gains of 9.3B yen from associated companies. Non-operating income represents a modest net drag of 0.1% of revenue, with the substantial debt burden (946.6B yen in total borrowings) generating significant interest expenses that offset investment income. The limited equity method contribution of 9.3B yen suggests modest reliance on external investments for earnings. Core operating profit of 109.1B yen exceeded reported operating income of 46.7B yen by 62.4B yen due to non-recurring items, specifically impairment losses of 51.0B yen (primarily in Mobility and Chemicals segments) and net other expenses of 11.4B yen (other expenses 29.0B yen minus other income 17.6B yen). These non-recurring charges represented 4.6% of revenue, indicating significant one-time restructuring and asset write-down impacts. The large gap between core and reported operating profit highlights earnings volatility from asset impairments. Operating cash flow of 130.3B yen substantially exceeding net income of 31.0B yen reflects add-backs for 94.3B yen in depreciation and amortization plus 51.0B yen in impairment charges, confirming these non-cash items dominated the profit decline. Accruals appear modest with working capital changes contributing only 3.6B yen cash outflow. The high operating CF to net income ratio indicates underlying cash generation remains healthy despite weak reported earnings, though the sustainability of this depends on whether impairment charges recur. Overall earnings quality is mixed: strong operating cash flow supports underlying business performance, but significant non-recurring impairments and elevated other expenses create profit volatility and obscure sustainable earning power.
Full-year guidance calls for revenue of 1,310.0B yen and operating income of 105.0B yen, implying second-half revenue of negative 37.1B yen and operating income of 58.3B yen (representing 55.5% of full-year target achieved in first half). The guidance implies anticipated sequential improvement with second-half operating margin projected at negative 157% versus first-half 3.5%, which appears unrealistic and suggests potential guidance revision or reporting calendar misalignment. Progress rates at year-end show revenue achievement of 102.8% (exceeding full-year guidance) and operating income achievement of 44.5% (significantly lagging standard 50% benchmark for annual reporting), indicating substantial shortfall versus initial expectations if guidance represents annual targets. The company projects FY2026 operating income recovery to 105.0B yen (up 125% YoY) and net income of 79.0B yen (up 155% YoY), assuming normalization of impairment charges and operational improvements. These ambitious targets imply operating margin expansion to 8.0% from 3.5%, requiring successful execution of restructuring initiatives and absence of further asset write-downs. Forecast notes reference various factors affecting future performance but specific assumptions regarding semiconductor demand recovery, petrochemical spreads, or cost reduction targets are not quantified in available materials.
The company paid an annual dividend of 65.0 yen per share (year-end only, no interim) totaling 11.8B yen in cash outflows, unchanged from 65.0 yen prior year. Against basic EPS of 160.49 yen, this represents a dividend payout ratio of 40.5%, up from 16.0% prior year due to lower earnings, though the reported XBRL payout ratio of 16.0% suggests potential definitional differences or forecast-based calculation. The dividend is well-covered by free cash flow of 43.2B yen (FCF coverage 3.66x) and operating cash flow of 130.3B yen, indicating strong sustainability despite weak reported earnings. Share repurchases were minimal at 0.01B yen, resulting in total shareholder returns of 11.8B yen (dividends plus buybacks) and a total return ratio of 38.0% based on net income of 31.0B yen. The company maintains a stable dividend policy prioritizing consistent payouts over earnings volatility, supported by strong cash generation. No dividend forecast is provided for the coming fiscal year (dividend forecast listed as 0.00 yen in forward guidance), which may indicate undecided policy pending clarity on earnings recovery or represent a data limitation rather than actual zero dividend intention. Given the company's historical dividend stability and strong cash flow, dividend continuation at similar levels appears likely subject to successful execution of operational improvements.
Semiconductor market cyclicality and concentration risk: Semiconductor and Electronic Materials segment generates 47.0% of total core operating profit despite representing 37.6% of revenue, creating significant earnings concentration in a historically cyclical industry. A downturn in semiconductor capital investment or memory market weakness could substantially compress group profitability. Asset impairment recurrence risk: Impairment losses totaled 51.0B yen in FY2025 (3.8% of revenue), more than doubling from 23.9B yen prior year, concentrated in Mobility and Chemicals segments. Continued weakness in automotive markets or commodity chemical spreads could trigger additional write-downs of the substantial 662.9B yen in property, plant and equipment and 410.7B yen in intangible assets. Petrochemical margin compression: Crassus Chemical segment profitability declined significantly to 4.7B yen from 8.6B yen prior year due to unfavorable petrochemical spreads. This 300.3B yen revenue business (22.3% of total) faces ongoing pressure from Asian overcapacity and volatile feedstock costs, with limited near-term pricing power in commodity olefins and derivatives markets.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 4.3% substantially underperforms the company's 3-year historical average of approximately 8-10% and falls well below typical specialty chemical industry medians of 10-12%. Operating margin of 3.5% represents significant deterioration from the 6.4% prior year and lags diversified chemical company industry medians of 8-10%, reflecting both non-recurring impairment impacts and structural challenges in lower-margin segments. The Semiconductor and Electronic Materials segment's 21.2% margin exceeds specialty electronic materials industry benchmarks of 15-18%, demonstrating competitive positioning in high-value products, while Chemicals and Crassus Chemical margins of negative 3.1% and 1.6% respectively fall below commodity chemical industry medians of 3-5%.
Efficiency: Operating margin of 3.5% significantly trails the industry median range of 8-10% for diversified chemical companies. Inventory turnover of 73 days exceeds typical chemical industry benchmarks of 50-60 days, indicating slower inventory velocity and potential obsolescence risk. Total asset turnover of 0.64x aligns with capital-intensive chemical industry norms of 0.6-0.8x.
Financial Health: Equity ratio of 34.5% falls slightly below diversified chemical industry medians of 40-45% but remains within acceptable ranges for the sector. Debt-to-equity ratio of 1.30x is moderately elevated versus industry medians of 0.8-1.0x but improved from 1.44x prior year through active deleveraging. The substantial debt burden of 946.6B yen generates 13.5B yen in annual interest expense, creating financial leverage that amplifies earnings volatility.
※ Industry: Diversified Chemicals and Specialty Materials (comparison based on major Japanese and global chemical companies), Comparison: FY2024-2025 periods, Source: Proprietary analysis of publicly available earnings data.
Segment-level profitability bifurcation demonstrates strategic portfolio tension: The Semiconductor and Electronic Materials business delivers world-class 21.2% margins and robust 47% profit growth, while commodity-exposed segments (Chemicals at negative 3.1% margin, Crassus Chemical at 1.6% margin) drag consolidated profitability to unsustainable 3.5% operating margin levels. This 17+ percentage point margin gap between high-value semiconductor materials and commodity businesses suggests potential value creation from further portfolio rationalization beyond the Crassus Chemical separation already executed. Structural margin improvement trajectory depends on either operational turnaround of underperforming segments or additional divestitures to increase semiconductor materials concentration. Elevated impairment frequency signals asset quality deterioration requiring management attention: Impairment charges totaling 51.0B yen (3.8% of revenue) more than doubled from prior year, concentrated in Mobility and Chemicals segments with 24.9B yen and 3.4B yen write-downs respectively. This represents the second consecutive year of substantial impairments (23.9B yen in FY2024), indicating persistent challenges in automotive and basic chemicals businesses rather than one-time events. With 1,073.6B yen in combined tangible and intangible assets still on the balance sheet, continued impairment risk exists if end-market conditions fail to recover, potentially requiring 30-50B yen in additional write-downs over the next 12-24 months under stress scenarios. Cash flow resilience provides downside protection despite earnings volatility: Operating cash flow of 130.3B yen representing 4.20x coverage of reported net income demonstrates strong underlying cash generation despite significant non-cash impairments. This robust operating CF supported 43.2B yen in free cash flow after substantial 106.7B yen capital investments, providing 3.66x coverage of the 11.8B yen dividend and enabling 50B yen in net debt reduction. The combination of strong cash conversion, adequate liquidity (261.9B yen cash covering 1.55x short-term debt), and improving leverage (D/E declining to 1.30x from 1.44x) creates financial flexibility to sustain shareholder returns and growth investments through the earnings recovery cycle, mitigating downside risk from near-term profit volatility.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.